hVIVO plc Directors' Dealings (2900B)
09 January 2018 - 6:00PM
UK Regulatory
TIDMHVO
RNS Number : 2900B
hVIVO plc
09 January 2018
For immediate release 7.00am: 9 January 2018
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with
discovery and clinical testing capabilities, announces that
application has been made to AIM for the admission of 23,675 new
ordinary shares of 5.0p each in the Company (the "New Ordinary
Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jaime Ellertson (Non-Executive Chairman) and Jim
Winschel (Non-Executive Director) of new ordinary shares, under the
terms of their letters of appointment as set out in the Company's
announcement of 4 November 2014 which stated that Mr Ellertson and
Mr Winschel had entered into binding commitments to purchase
$20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively
per quarter. On 7 June 2017 Jaime Ellertson volunteered to reduce
his Director's fee by 10% to $180k pa, then on 13 November 2017 his
role changed from Non-Executive Chairman to Non-Executive Director
and his Director's fee reduced to GBP50k pa. His quarterly purchase
of shares has reduced accordingly as 40% of his Director's fee.
The New Ordinary Shares represent their investments for the
quarter ended 31 December 2017. On 8 January 2018, Mr Ellertson
invested in an additional 16,401 ordinary shares and Mr Winschel
invested in an additional 7,274 ordinary shares, at a price of 55.0
pence per share.
Following admission of the New Ordinary Shares to trading on
AIM, the total number of ordinary shares with voting rights in
issue will be 78,197,542 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 11 January 2018. Following
Admission, Mr Ellertson and Mr Winschel will be interested in a
total of 128,814 and 57,397 ordinary shares of 5.0p in the Company
respectively, representing 0.2% and less than 0.1% of the Company's
issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial
responsibilities/persons closely associated
--- -----------------------------------------------------------
a) Name Jaime Ellertson and Jim Winschel
--- ----------------- ----------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/ Non-Executive Director
status
--- ----------------- ----------------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ----------------- ----------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------------
a) Name hVIVO plc
--- ----------------- ----------------------------------------
b) Legal Entity N/A
Identifier
--- ----------------- ----------------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the
financial
instrument, GB00B6ZM0X53
type of
instrument
Identification
code
--- ----------------- ----------------------------------------
b) Nature Acquisition of ordinary shares
of the
transaction
--- ----------------- ----------------------------------------
c) Currency GBP
--- ----------------- ----------------------------------------
d) Price(s) Director Price (p) Volume
and volume(s) ----------------- ---------- -------
Jaime Ellertson 55.0 16,401
----------------- ---------- -------
Jim Winschel 55.0 7,274
----------------- ---------- -------
--- -----------------
e) Aggregated
information
- Aggregated
volume
- Price 23,675
- Aggregated 55.0p
total
GBP13,021.25
--- ----------------- ----------------------------------------
f) Date of 8 January 2018
the transaction
--- ----------------- ----------------------------------------
g) Place of London Stock Exchange, AIM
the transaction
--- ----------------- ----------------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive
Officer)
Graham Yeatman (Chief Financial
& Business Officer)
Media Enquiries +1 919 710 9658
Susan Flood (Head of Marketing)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke
(Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster
Mitchell (UK) +44 203 727 1000
John Capodanno / Evan Smith
(US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with
discovery and clinical testing capabilities, is pioneering a
human-based analytical platform to accelerate drug discovery and
development in respiratory and infectious diseases. Leveraging
human disease models in flu, RSV and asthma exacerbation, the hVIVO
platform captures disease in motion, illuminating the entire
disease life cycle from healthy to sick and back to health. Based
in the UK, market leader hVIVO has conducted more than 50 clinical
studies, inoculated over 2500 volunteers and has three
first-in-class therapies currently in development with a growing
pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUGUQAGUPRPPR
(END) Dow Jones Newswires
January 09, 2018 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024